Tag: MILV

CNUV, EXTO, MILV – Hot Stocks Today

China Nuvo Solar Energy, Inc. CNUV

We are presenting CNUV as a momentum play this morning. On Wednesday, the stock traded over eleven times its 3mo avg. volume.

 

We cannot confirm the validity the following assertion, however, rumor has it that CNUV has a series of press releases planned, so we are going to leave the stock on our radar to see how the situation plays out.

 

The first of these releases went out this morning:  

 

WEST PALM BEACH, Fla., Nov. 3, 2011 /PRNewswire via COMTEX/ — China Nuvo Solar Energy, Inc. (OTCQB: CNUV) today announced that it has signed a Non-Binding Letter of Intent (“LOI”) to acquire a distributor of surgical implants. Pursuant to the terms of the LOI, the Company has contemplated that upon the anticipated closing of the transaction that the target distribution company would become a new wholly owned subsidiary of CNUV.

 

Exit Only, Inc. EXTO

We are still bullish on EXTO. Yesterday the stock continued to achieve higher highs and higher lows; currently the MACD is converging toward an imminent cross, which will only serve to increase our bullish sentiment.

Mistral Ventures Inc MILV

Another stock with anticipatory news out yesterday is MILV. It was basically an allusion to another development that should be occurring within the next week.

In the meantime, MILV has provided traders with continual opportunity. Yesterday saw a high of .10, a gain of 82% from our first alert at .055.

As with RAYS, MILV has enjoyed a long period of positive flow, so an argument can be made for taking profits. At the very least, one should remain vigilant as the stock is beginning to appear slightly overbought.

CAPE CORAL, Fla., Nov. 2, 2011 /PRNewswire via COMTEX/ — Nature’s Bioceuticals, a wholly owned subsidiary of Mistral Ventures Inc. (MILV.pk – News) announced that it has reached an agreement in principal with the inventor of a formula that could have life changing results for hundreds of millions of people worldwide afflicted with the disease. It is expected that the formal agreement will be executed in the coming week, at which point details of the product will be released.

EXTO, RAYS, MILV – Hot Stocks Today

Raystream Inc. RAYS

Those of you that recall our alert of RAYS at 1.36, dating back to the stock’s second day of trading, have witnessed over a 1.00 in gains (74%)

 

As we stated last Friday, RAYS is a heavily promoted stock, with an estimated $2.3M promotional budget. We just want to make it clear, that extreme caution should be exercised with this stock.

 

There have been no press releases direct from RAYS that have presented anything of real substance concerning the company’s plan to take their technology to market. Thus far we have heard a lot of forward-looking statements, and seen a lot of paid promotions but nothing more.
The opportunity to make money with the stock still exists, of course, we just have our guard up with RAYS.

Exit Only, Inc. EXTO

EXTO  closed at its high of day of .0066 on Tuesday, marking a 35% gain from the low of .0049 on Monday.

 

On Monday, we pointed out the fact that EXTO was clearly oversold, as evidenced in the RSI, which began moving back up yesterday, and is now pointing north.

 

EXTO is capable of making rapid moves, we have seen it before. We are still waiting for the company to bring their filings up to current with OTCMarkets.com, at which time we should finally receive an update on the company’s operations.

 

We still think there is plenty of upside potential for EXTO.

 

Mistral Ventures Inc MILV

Our momentum alert from a week past, has taken a wild ride since we mentioned it at .055. The high of .081 on Tuesday represents a gain of 47%Not too shabby for a week’s worth of observation, and a figure that puts our collective gains over the past couple of weeks well over 200%

The stock is a daytrader’s delight, providing plenty of dips and surges to play, and we expect to see that trend continue moving forward.

JVA, EXTO, MILV, SRRL – Hot Stocks Today

Coffee Holding Co., Inc. JVA

We initially cited our interest in JVA at 8.35, and the stock ran as high as 14.40 for a 72 percent gain. On Friday, the stock closed at 11.30, still a gain of 35 percent from our originating call.

Moving forward, JVA will remain on our watchlist for its prime performance, and our expectation that there are more positives on the horizon.

 

Exit Only, Inc. EXTO 

It has been quite some time since we mentioned EXTO, a stock that first popped onto our radar in July, thereupon making a massive move for us.

Last week, there was a large volume selloff, and we saw a retrace to the lowest price we have seen since July. Currently the RSI smacks of overselling, which is why we presumed to mention this play again, as a rebound from these conditions and prices seems highly plausible.

 

Stellar Resources, Ltd. SRRL

We have noticed that after a big sell-off, the stock is building support in the .02 range, and it is going to be interesting to see how the stock trends, as it begins to rebound off of its bottom.

Just 2-3 weeks back , the stock was trading in the five to six cent range, and we believe it could easily return to that level, which would yield gains of over 100-200 percent.

 

Mistral Ventures, Inc. MILV

We wanted to mention MILV again this morning, after some post-market news on Friday could really cause a stir, considering the nature of the company’s claims. If even a fraction of the estimated revenue from the following press release materializes for MILV, the results could be satifying for investors.

 

CAPE CORAL, Fla., Oct. 28, 2011 /PRNewswire via COMTEX/ — Nature’s Bioceuticals, a wholly owned subsidiary of Mistral Ventures Inc. (MILV.pk) announced that it has come to an agreement for the purchase of the newly formulated Sinus-Restore Sinus Relief Formula. Nature’s has tendered a deposit against formal closing, which is expected within 3 weeks. At the request of the inventor, to protect his privacy, financial terms are not to be disclosed in press releases.

 

The Center for Disease Control and Prevention estimates that close to 31 million adults in the US suffer from chronic sinusitis, resulting in 12.5 million ambulatory care visits per year and more than 200,000 sinus surgical procedures every year. Acute sinusitis is even more common, though there are no good estimates for the number of people who experience an episode of acute sinusitis every year.

 

Robert deZanger, CEO of Nature’s Bioceuticals states, “We are excited about bringing this product to market. Approximately 13% of the adult population suffers from chronic sinusitis. Billions of dollars per year are wasted on doctor visits and antibiotics that are unnecessarily prescribed to treat viral infections for which they will not help. Our all natural product has been shown to provide relief in a few short days. We expect to finalize the purchase within the next 21 days and to have product manufactured and ready for sale approximately 21 days thereafter. The product should also have far reaching impact for the relief of nasal discomfort due to allergies and cold and flu. The product is inexpensive to produce and we believe it will command a substantial market share in the three different markets therefore producing substantial revenues for the company. We anticipate sales in excess of $10,000,000.00 the first year and then expanding exponentially thereafter.”